Hydroxypyruvic acid lithium hydrate
Modify Date: 2024-01-11 18:37:33
Hydroxypyruvic acid lithium hydrate structure
|
Common Name | Hydroxypyruvic acid lithium hydrate | ||
|---|---|---|---|---|
| CAS Number | 209728-15-4 | Molecular Weight | 128.01 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C3H5LiO5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Hydroxypyruvic acid lithium hydrateHydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway. |
| Name | Hydroxypyruvic acid lithium hydrate |
|---|
| Description | Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway. |
|---|---|
| Related Catalog | |
| Target |
IC50: intermediate; substrate |
| In Vivo | Hydroxypyruvic acid (lithium hydrate) (intravenous injection; 100 mg/ml; slowly over 10 min) increases the 5-h urinary oxalate and glycolate excretion to 0.68% (6.56 μmol) and 0.53% (5.10 μmol) in control rats, in addition, it increases to 2.43% (23.36 μmol) and 0.79% (7.59 μmol) of the dose in the vitamin-B6-deficient rats[1]. |
| References |
| Molecular Formula | C3H5LiO5 |
|---|---|
| Molecular Weight | 128.01 |